Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NRT more effective than placebo

This article was originally published in The Tan Sheet

Executive Summary

Nicotine replacement therapy helps smokers quit and abstain more effectively than a placebo, according to a meta-analysis published online April 2 by the British Medical Journal. A review of seven randomized, placebo-controlled trials of NRT use shows 6.75 percent of smokers using NRT abstained from smoking for six months - twice the rate of smokers using a placebo. Researchers led by David Moore at the School of Health and Population Sciences at the University of Birmingham added that 8.7 percent of study participants tolerated NRT with no adverse effects except some nausea. NRT marketers cite smokers' greater chances of successfully quitting in advertising for the products (see related story)

You may also be interested in...

Cigarette Tax Hike Sparks NRT Marketing Opportunities

A 62-cent federal cigarette tax hike may push smokers to quit the increasingly expensive habit - creating a marketing opportunity for nicotine replacement therapy makers

Future Use Of Titanium Dioxide In Spray And Powder Cosmetics Hinges On SCCS Review

As of 5 February, the Scientific Committee on Consumer Safety is evaluating use of titanium dioxide – now officially classified as a Category 2 carcinogen in the EU – in cosmetic products that can expose consumers by way of inhalation. Without a favorable SCCS opinion, the ingredient’s use in those contexts will be banned under Article 15 of the Cosmetics Regulation.

Nanobiotix CEO’s Expansion Plans Target ‘Millions’ Of Patients

Nanobiotix’s CEO outlines to Scrip how the biotech plans to develop and expand its lead asset into multiple cancer indications, and create a blockbuster.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts